Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development


Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections.

CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53) for potential development of a live-attenuated Zika vaccine. These chimeric viruses could also be used for other research purposes such as development of diagnostic tests. The cDNA genetic clones for the chimeric constructs have been successfully engineered, and scientists in the laboratory are in the process of deriving infectious chimeric D2 PDK-53/Zika viruses.

Potential Commercial Applications: Competitive Advantages:
  • Zika vaccine development or combined vaccination strategies using both live-attenuated and inactivated ZIKV vaccine (West Nile/ZKV) candidates
  • Combination vaccine with other flaviviruses such as dengue or chikungunya
  • Zika virus diagnostics
  • Zika virus-related biomedical research
 
  • Potential inclusion in combination flavivirus vaccines
  • Faster production of Zika-like viruses for more efficient use in different applications such as vaccine candidate and diagnostic development


Related Invention(s):
E-118-2016-0


Inventors:

Claire Kinney (CDC)  ➽ more inventions...


Intellectual Property:
US Application No. 62/359,812
PCT Application No. PCT/US2017/040820

Collaboration Opportunity:

The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Chimeric Dengue/Zika Viruses for Zika Vaccine Development. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.


Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-178-2016-0
Updated: Jun 8, 2018